- Home
- LAES vs TNGX Comparison
LAES vs TNGX Comparison
Compare LAES & TNGX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- LAES
- TNGX
- Stock Information
- Founded
- LAES 2022
- TNGX 2014
- Country
- LAES Switzerland
- TNGX United States
- Employees
- LAES N/A
- TNGX N/A
- Industry
- LAES Semiconductors
- TNGX Biotechnology: Pharmaceutical Preparations
- Sector
- LAES Technology
- TNGX Health Care
- Exchange
- LAES Nasdaq
- TNGX Nasdaq
- Market Cap
- LAES 315.9M
- TNGX 317.4M
- IPO Year
- LAES N/A
- TNGX N/A
- Fundamental
- Price
- LAES $3.03
- TNGX $1.67
- Analyst Decision
- LAES Strong Buy
- TNGX Strong Buy
- Analyst Count
- LAES 1
- TNGX 7
- Target Price
- LAES $6.00
- TNGX $12.33
- AVG Volume (30 Days)
- LAES 11.6M
- TNGX 853.8K
- Earning Date
- LAES 04-08-2025
- TNGX 05-07-2025
- Dividend Yield
- LAES N/A
- TNGX N/A
- EPS Growth
- LAES N/A
- TNGX N/A
- EPS
- LAES N/A
- TNGX N/A
- Revenue
- LAES $10,981,000.00
- TNGX $42,069,000.00
- Revenue This Year
- LAES N/A
- TNGX N/A
- Revenue Next Year
- LAES N/A
- TNGX N/A
- P/E Ratio
- LAES N/A
- TNGX N/A
- Revenue Growth
- LAES N/A
- TNGX 15.17
- 52 Week Low
- LAES $0.29
- TNGX $1.60
- 52 Week High
- LAES $11.00
- TNGX $12.02
- Technical
- Relative Strength Index (RSI)
- LAES 48.66
- TNGX 32.02
- Support Level
- LAES $2.79
- TNGX $1.65
- Resistance Level
- LAES $3.22
- TNGX $1.81
- Average True Range (ATR)
- LAES 0.32
- TNGX 0.16
- MACD
- LAES 0.06
- TNGX 0.01
- Stochastic Oscillator
- LAES 45.64
- TNGX 8.57
About LAES SEALSQ Corp
SEALSQ Corp develops certified secure microcontrollers and implements post-quantum cryptography. The company develops solutions including post-quantum microchips and devices that can be used in a variety of applications, from multi-factor authentication, home automation, and IT network infrastructure to automotive, industrial automation, and control systems. Its vaultIC range offers a complete set of ready-to-use secure elements designed to implement embedded security for any kind of device with fast time-to-market and high flexibility. The company's products include VaultIC155, VaultIV18x, VaultIC292, and VaultIC40x. The company generates a majority of its revenue from North America.
About TNGX Tango Therapeutics Inc.
Tango Therapeutics Inc is a biotechnology company. It is dedicated towards discovering novel drug targets and delivering the next generation of precision medicine for the treatment of cancer. It is engaged in the business of discovering and developing precision oncology therapies. Its program TNG908, is an MTA-cooperative inhibitor of PRMT5 designed to work selectively in cancer cells with an MTAP deletion. Its pipeline further consists of discovery programs such as, TNG462, TNG348, TNG260 and others for multiple cancer types with limited treatment options.